Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02073487
Title Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Acronym TEAL
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors The Methodist Hospital System
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.